Patents Assigned to Biomethodes
  • Patent number: 8623824
    Abstract: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: January 7, 2014
    Assignees: Biomethodes, Hospices Civils de Lyon
    Inventors: Didier Saboulard, Jean-Luc Plantier, Marc Delcourt, Claude Negrier, Thierry Menguy, Stephane Blesa, Sylvie Marin
  • Patent number: 7202086
    Abstract: The invention concerns the field of molecular biology and more particularly that of mutagenesis. It concerns a method of high-rate directed mutagenesis, that is the formation of numerous directed mutants in reduced time and with reduced number of steps. Said method is therefore referred to as massive mutagenesis.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: April 10, 2007
    Assignee: Biomethodes
    Inventors: Marc Delcourt, Stephane Blesa
  • Patent number: 6924112
    Abstract: The present invention pertains to a process for isolating an intact clone of one target nucleic acid fragment having a known characteristic, from a group of fragments by preparing an initial library of clones from the group of fragments using a vector containing no more than a predetermined number of known restriction sites, preferably 1–3 restriction sites, subjecting the initial library to at least 10, and preferably between 50 and 70 restriction enzymes different from those to which the vector is susceptible, to produce a group of monodigested libraries, screening the group of monodigested libraries for the target fragment to determine those restriction enzymes to which the target fragment is insensitive, and subjecting the initial library to substantially all of the restriction enzymes to which the target fragment is insensitive, to produce a multidigested library having an intact clone of the target nucleic acid fragment.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: August 2, 2005
    Assignee: Biomethodes S.A.R.L.
    Inventor: Marc Delcourt